Abliva : doses the first patient in its KL1333 Phase Ia/b clinical study

Print Friendly, PDF & Email

Abliva AB (Nasdaq Stockholm: ABLI) today announced that the first primary mitochondrial disease patient in the company’s ongoing KL1333 Phase Ia/b study has been dosed. In this third part of the study, the pharmaceutical properties of KL1333 will, for the first time, be evaluated in patients. Eight patients with […]